Member Info for The_Paladin

"Price target of $2.88 - $2.96 within the year predicted, by March 2024".

This corresponds to the maximum spike price reached following the meteoric rise in 2020. This is well beyond my current price target of 100p. I have no real rationale as a basis for that target, but should have a better idea of our prospects one there is further information from the company. My price reflects my selling price for a decent profit, nothing else.

However, when I apply logical reasoning to the current situation, it seems highly unlikely that a scenario suggested by Ab4, and the crazy gang on the advfn board, will be our endpoint. It would be reassuring to receive some encouraging news at present; presumably the CEO will have something to add before the AGM? If not, I suspect that he will be fielding some very difficult questions from frustrated investors? GLALTIs

Yesterday's acquisition:
Pfizer CEO Albert Bourla Announces Acquisition of Cancer Treatment Biotech Seagen For $43 Billion
“1-in-3 people in the world are going to have cancer in their lifetime…This is something like the mRNA for vaccines, [but] this is for cancer.”

Anyone who is comparing yesterday's acquisition of Seagen with potential M&A activity involving Synairgen has not given the matter a great deal of thought? A large pharmaceutical entity could acquire a relative minnow like Synairgen at a fair price, to reflect what has been achieved to date, without a noticeable effect to its M&A fund. Ab4 loses further credibility by suggesting such a ridiculous comparison IMHO. One wonders why there is such a flurry of activity from the aforementioned "sage"? As said previously, he is merely stating the obvious. A decline in share price ion any AIM company in the absence of a significant update isn't rocket science.

"The lady doth protest too much, methinks."

GLALTIs

The share price is back to where it was before Synairgen’s meteoric rise in 2020. Let’s forget about the dosing patients by the end of Winter comment. It has long been apparent that it was a non- starter and should not have been put forward with nothing to substantiate it.

Importantly, does the company have a forthcoming announcement to counteract the continuously declining share price? We will soon find out whether the CEO’s B-road spectrum antiviral “strategy” will lead to a recovery, or whether we have had the wrong people at the helm for well over a year?

It is uncomfortable for any investor to witness the current decline, without anything of substance on the horizon. We may yet see a recovery, but for the time being it has all been an apparent inaction, accompanied by a continuous share price decline.

GLALTIs.

Hi Professional,

What you say makes reasonable sense. To clarify a few points:

“having no choice but hope and wait”
There has always been the choice to sell and move on. Some investors have done just that. Some claim that they have partly/totally regained their losses. I applaud their better judgement. However, having remained with this investment for over a year, it would be foolish to sell at this point in time - year low share price and downwardly trending in the absence of news that the market would deem to be significant. It is ironic that when TFG started to add over a year ago, it would have been an excellent time to sell at the 30p - 40p spike. At today’s price, it is better to hold and trust the company to arrange a suitable route forward IMHO.

“If they wanted their own timelines they should have stayed at University.”

Yes, it is painfully slow, but the company can probably do nothing about it? I do not fully understand the process, but there needs to be a confluence of complex information before any suitable transactions can be agreed upon. This sector is known to move at glacial speed, and this will continue in our case until all the information is in place to secure a deal.

All LTIs remain frustrated at the stagnation. Our options are simple - either wait/hold/add/trade etc whatever strategy one adopts, or make a clean break of it and move on.

As stated previously, I am holding indefinitely in hopeful anticipation of an approximate x10 gain? Neither confident nor unconfident ATM but reasonably optimistic. There is no point in being otherwise.

Good luck to you and to all LTIs

Professor Wilkinson was involved both in Synairgen's P2 Home trial, and in the Sprinter trial. He participated in the webinar, which accompanied the former trial. Additionally, following the Sprinter trial, he commented that there was sufficient merit in the data to warrant a further platform trial. He was one of the co-authors of the scientific paper summarising the Sprinter trial findings that was published last December.

My interpretation is that as a professor at Southampton University, he is on site to lend his assistance as a consultant, whenever it is needed?

GLTALTIs.

I agree with dunk1973.

Any LTI/trader, who frequents this forum, is hardly likely to pay any attention to the scaremongering remarks of a small number of posters. I recently removed my filters, and engaged in conversation with one of them. His/her response convinced me that his/her "opinion" is nothing but an educated guess based on the SNG share price trend. They are all wasting their time IMHO. If their remarks bother you, they should be green binned; otherwise their comments should be taken with a pinch of salt.

There have been some interesting points of view contributed this weekend. I recently studied my notes going back about 10 months. I was annoyed with Synairgen's personnel at the time; this is no longer the case. The company has moved forward since then, although Synairgen's precise future strategy remains" hidden" for the time being? Perhaps there are a number of alternatives under consideration? As someone remarked earlier, we will most probably have a definitive statement by the next AGM, if not earlier? I now tend to agree with Fruits' "Michael Caine esque" remark about preferring to wait for an RNS which would "blow the doors off", and cause the share price to rise beyond its current year-low trough. We can but remain optimistic, based on what is currently known. There is no point in thinking otherwise.

FWIW, my long term target is now 100p. At that point, I would either sell my entire shareholding with a decent profit, or else take all my original investment off the table, and leave the remaining "free" shares in anticipation of further gain. I suspect that I may need to wait a long while before taking that decision ?

Meanwhile, my thanks to all contributors, who help to shape my thinking in these uncertain times.

GLALTIs.

Much has been written in this forum about this issue in relation to the quality of Synairgen's communication over the last year. It is an interesting topic and one that merits research. These particular comments are relevant to our current situation. There have been changes in the corporate world since they were published, but the content applies to any business aiming for good relations with its investors.

"Confidence is crucial in investor relations. If the CEO can drive the IR process effectively by telling a good story, it will ultimately impact the bottom line. This means courting shareholders and analysts and telling the right story to capture the imagination of new investors; and reassure existing ones. But how frequently should the market be updated and which channels are most effective?

Every CEO wants to see increased shareholder value. But it’s not easy balancing the inherent short-termism of being a listed company with making the tough decisions that are in the long-term interests of the business. The CEO must present a consistent message to the market and be clear in every communication. After all, one wrong statement could lead to disaster."

This section is particularly relevant.

"Eventually, every CEO may face the prospect of failing to meet expectations. While there is no tangible profit to be made from updating the market, this communication could be the CEOs most important transaction – not least as a test of deal brokering and negotiation – as the value of the company could be altered drastically based on what is or isn’t said."

On the strength of these principles, it is difficult to judge our CEO's competence without having full knowledge of the company's short-term and long-term aspirations? I will reserve making any further judgement until I receive that long-awaited concrete news from Synairgen. The sooner something happens, the better it will be for us all.

GLALTIs

This was flagged up on my twitter account as a contribution from a Synairgen employee. Anyone, who has visited her online account will already know that Mrs. Clarke is a good, and genuine person.

“Today is a day to recognise the millions of people around the world living with rare diseases and to honour the dedicated researchers, healthcare professionals, advocates, and families that work tirelessly to find treatments and cures. Let's celebrate the progress that we have made and keep the fires burning. #rarediseaseday2023 #rarediseaseawareness”

TommyD_19.

“When Paladin tell us the company have done nothing for a year, I’ll be here to show what they’ve done..”

We all know what has been achieved. Essentially, they have paid external consultants to analyse and extract all the meaningful data from their trials. This information has been presented in various formats at conferences, mostly in the US. We have been presented with a nebulous “strategy” without definite goals or timelines. We have no idea of the how or when our investment is going to progress this year, or next? Should the company fail to attract external investment, the last resort will be another fund raise with further dilution, and no guarantee of success from a company-led trial, if their last two endeavours are anything to go by.

Yes, they have tidied the store this year, but have no products on sale. They do not have a business.

Finally, now that Docdaneeka has opened the Pandora’s box, here are a few home truths from me. Your attempts at pointing an accusing finger at me, as though I were some kind of dissembler is a figment of your imagination. There is nothing in my posts that might lead an intelligent individual to that conclusion. Your high handed approach will win you few friends. A few of us have tried to reply respectfully to your comments, without any concession from your side. I wish you well with your investments, but will not waste my energy in responding to your sarcasm in future.

GLALTIs

Hi Professional,

“People who feel the need to call people with a different view mentally ill ……”

My comments, a few posts ago, was not directed at individuals with different opinions about this investment. I was targeting those individuals, who resort to online abuse towards Synairgen investors like myself, who are currently well down in our portfolios. Fortunately, this kind of behaviour doesn’t happen too often on this forum. To see some examples, you will need to view the advfn board. I remain firm in my belief that any individual who resorts to serious online abuse of this description for any reason most probably suffers from a psychological disorder?

It is interesting that Trinityman’s post, that quoted actual evidence of this kind of behaviour with some analysis earlier today was cancelled?

All the best . T_P

Thank you Trinityman.

I recall, a short while ago, that you mentioned that you would share your observations on inappropriate behaviour with the forum. Having read your comments, I agree with your thorough assessment of the situation.

I tend to take this kind of online abuse with a pinch of salt, and put it down to the psychological condition of the perpetrators. Some of these have flawed personalities to say the least. I stopped using the advfn board due to a similarly inclined, though less intelligent, narcissistic individual, who was persistently trying to take command of the narrative.

Not for the first time, this forum descended into chaos yesterday, and I wasn’t surprised to see threads removed from the overall conversation.

I remain fully invested here. Despite my disappointment of the CEO’s lack of communication, my confidence in SNG001’s potential remain intact. As stated earlier, there are different possible outcomes to this investment. Investors should IMHO remain in anticipation of a positive RNS statement identifying a route to the commercialisation of Synairgen’s product.

All the very best. T_P.

TommyD_19.

Synairgen have had over a year to focus on the big issues. It is reasonable for investors to be disaffected by the fact that there has been no measurable progress in that time? Today the share price is at its year low - a reflection of Synairgen’s NAV?

I remain confident of a good outcome to my investment, but am uncertain whether it will happen through the efforts of Synairgen, or via an external intervention? You are right in saying that TFG Holdings , who have remained backstage until now, may make their voice heard should the current inaction continue for much longer?

I hope that you are right Peakhope. My biggest mistake was in not selling all my shares towards the end of December 2021, when a small profit was possible. There have been some good trading opportunities since then. However, I am a LTI, and do not look upon the market from a traders perspective. It has been a long wait. Surely, we have a strong possibility of a re-rate well above the current share price trough this year? Patience is needed. This is sometimes difficult, but an essential attribute of any SYME LTI.

Thank you for your insightful comments, which I value. GLALTIs.

Does the statement mean share buys > 10K? I was thinking the same myself this week.

The dispiriting factor is the daily reduction in the share price. This is not uncommon in AIM shares. Despite the progress made in tidying the store this last year, and the considerable effort made by the company in spreading its message, we are still waiting for news to change the paradigm by which the market is currently viewing Synairgen.

By my calculations, the share price probably reflects the company's NAV at the present time? The cash burn is probably higher than it should be as a number of senior staff were hired for specific roles. Through no fault of their own, they are currently surplus to requirement.

I do not believe the CEO's statement attesting to the fact that they are needed for trial negotiations etc. We are constantly paying external consultants and specialist companies to provide assistance. This is sometimes necessary. I still maintain, despite others on this forum taking an opposite view, which I accept may well be the case, that the company should be able to recruit a lab technician without resorting to using an expensive external agency?

My comments probably reflect my disappointment with the CEO and others within the company. Not only for the fact that the share price, one year after a major disappointment, is achieving a new year low value each successive day? The lack of a definitive strategy statement, and lack of any progress being made, in the broadest terms, add to my current disaffection. I accept the viewpoint of others who maintain that the company is busy with ongoing negotiations ? / NDAs in place? ? / not allowed to divulge market sensitive information? etc etc The same is true of other companies, for example IQ-AI. They went through a long quiescent period similar to Synairgen's. However, the company's CEO issues a newsletter with updated non -sensitive information to shareholders every 3 months. Each of these gave more information than our CEO's new year statement, which was a reiteration of old information in chronological order together with a nebulous open ended "strategy".

I remain optimistic about the company's future despite the lack of communication, in particular from our CEO, who could have made more of an effort over the last 12 months. We simply cannot continue to present the Sprinter results at more conferences this year, and produce further non essential information on twitter/Linkedin which make no impact on the market. Should this lack of progress continue, perhaps changes in the leadership team may be necessary to find a way forward?

GLALTIs.

No Mr. Costs, but anyone who repeatedly bores the masses with the same facts has a problem of some description? There is nothing to dispute in your narrative. Historical facts are there for all to see. But do we need them rammed down our throats with such regularity? I think not.

Good luck to you. If you are as heavily invested as you claim, this share way well add considerably to your net worth in the future?

Thank you Fruits. I do not doubt that you are right, but IMHO it is odd that a tiny company, with limited resources, would employ an expensive recruitment consultancy to produce a job advert for a minor role? Surely there is sufficient talent within the company to attend to such a simple task?

We have turned a corner at long last. There are now several possible scenarios ahead. Happy to have invested in IB, which has always shown the potential to come to fruition in a major way. IB is a very well run company, with talented individuals, and who regularly keep investors informed about what is going on. This could end up as one of my better investments.

GLA.

Thanks Bryosa.

GLALTIs. FOAb4etal.

Well spotted BitetheBull. At first, I thought it might be a reference to the location of the technician’s place of work?

Like you Wigster, I had also had a long day, and couldn’t get my head around what was wrong with the text at first ? By the way, your punctuation is right out of the Mani playbook!! ( I remember your comments about it). I still haven’t got her syntax figured out?

GLALTIs. FOAb4etal.

I will continue with the latter as long as these de-ramping posts continue. The reality is that the downward spiral will inevitably continue until there is significant news. The same is true for all AIM shares in which I have invested. When Synairgen have a positive update, the shorters likely ke Ab4 will regret their overbearing and patronising comments.

Here is the list of key responsibilities for Synairgen's currently advertised Lab Technician post. Can you spot the error in the text?

Key responsibilities:

Responsible for processing and analysis of samples as delegated by the Research Scientist.

Analyse and interpret data in the context of the experimental aims and report in accordance with study needs.

Perform assigned responsibilities according to the non-clinical delegation log.

All work should be conducted in a manor satisfactory to ICH GCP and the regulatory bodies and in accordance with applicable SOPs.

Maintain adequate records (paper & electronic) and up-to-date lab book in accordance with relevant Standard Operating Procedures (SOPs).

Assist with audits/inspections as required.

Work must be conducted in a clean and safe working environment in accordance with the current version of the Synairgen Company Handbook and with Health and Safety policies, including: infection control, risk management and fire safety.

Adhere to good laboratory practice guidelines. Ensure equipment is used safely and maintained appropriately.

To be able to work to and meet deadlines, managing your own time effectively while also being flexible to clinical trial requirements.

To attend statutory training days, study days and company meetings necessary for the performance of the role and maintenance of your training file.

Develop professional and technical knowledge with a focus on respiratory disease and relevant laboratory techniques.

To maintain Synairgen confidentiality and IP and that of any clients / subjects at all times.